A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)

Trial Profile

A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOwER
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 09 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top